Research programme: multi-targeted cancer therapeutics - Curis

Drug Profile

Research programme: multi-targeted cancer therapeutics - Curis

Alternative Names: CU-0201; CU-201; CU-903; CU-906

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Curis
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Cyclin-dependent kinase inhibitors; Histone deacetylase inhibitors; Mitogen-activated protein kinase inhibitors; MTOR protein inhibitors; Src-Family kinase inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 18 Oct 2012 Curis files an IND application with the US FDA for refractory lymphomas and multiple myeloma
  • 04 Apr 2012 Pharmacodynamics data from preclinical studies in Cancer presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top